Prostate Cancer

Scope & Guideline

Elevating knowledge, enhancing lives in prostate cancer.

Introduction

Welcome to the Prostate Cancer information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Prostate Cancer, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2090-3111
PublisherHINDAWI LTD
Support Open AccessYes
CountryEgypt
TypeJournal
Converge2011, from 2013 to 2024
AbbreviationPROSTATE CANCER-US / Prostate Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON W1T 5HF, ENGLAND

Aims and Scopes

The journal 'Prostate Cancer' is dedicated to advancing knowledge and research in the field of prostate cancer, encompassing a wide range of topics from clinical treatment to psychosocial impacts. It aims to provide a platform for innovative research methodologies and significant findings that contribute to the understanding and management of prostate cancer.
  1. Clinical Treatment Strategies:
    Focuses on various treatment modalities for prostate cancer, including surgical, radiological, and pharmacological interventions, particularly in advanced stages such as castration-resistant prostate cancer.
  2. Diagnostic Innovations:
    Emphasizes the development and application of advanced diagnostic techniques, including imaging technology and machine learning, to enhance early detection and accurate staging of prostate cancer.
  3. Patient-Centered Research:
    Explores the psychosocial and health-related quality of life factors affecting patients, integrating patient-reported outcomes to better understand the impact of prostate cancer treatments.
  4. Neurocognitive Effects of Treatment:
    Investigates the cognitive side effects associated with prostate cancer therapies, particularly androgen deprivation therapy, to address the overall well-being of patients.
  5. Longitudinal Health Studies:
    Utilizes large-scale cohort studies to analyze trends in diagnosis, treatment outcomes, and factors influencing prostate cancer progression.
In recent publications, several emerging themes have become increasingly prominent within the journal 'Prostate Cancer'. These reflect contemporary challenges and advancements in the field, highlighting areas of growing importance for future research.
  1. Integration of AI in Diagnostics:
    The use of artificial intelligence and machine learning techniques for improving diagnostic accuracy and treatment personalization is rapidly gaining traction, indicating a shift toward more technologically advanced methodologies.
  2. Impact of Treatment on Quality of Life:
    Research focusing on the psychosocial aspects and quality of life post-treatment is on the rise, underscoring the importance of holistic patient care beyond mere survival rates.
  3. Longitudinal Studies on Patient Outcomes:
    There is an increasing trend in conducting longitudinal studies to track patient outcomes over time, providing valuable insights into the long-term effects of treatments and lifestyle factors on prostate cancer progression.
  4. Neurocognitive Research:
    Studies assessing the cognitive effects of prostate cancer treatments, particularly androgen deprivation therapy, are becoming more prominent, recognizing the broader implications of cancer therapies on patient mental health.

Declining or Waning

While the journal covers a broad array of topics, certain themes have shown a decline in focus over recent years. This reflects a shift in research priorities and emerging challenges in the field of prostate cancer management.
  1. Traditional Surgical Techniques:
    There appears to be a reduced emphasis on traditional surgical methods as newer, less invasive treatments gain attention and acceptance among researchers and clinicians.
  2. Basic Science Research:
    Research centered on the basic biological mechanisms of prostate cancer is becoming less prominent, possibly due to a stronger focus on clinical applications and patient-centered studies.
  3. Pharmacological Studies on Older Agents:
    There is a noticeable decrease in publications related to older pharmacological agents, as current research trends favor newer therapies that target specific pathways or utilize novel mechanisms.

Similar Journals

Research and Reports in Urology

Illuminating the future of urology with impactful findings.
Publisher: DOVE MEDICAL PRESS LTDISSN: 2253-2447Frequency: 1 issue/year

Research and Reports in Urology, published by DOVE MEDICAL PRESS LTD, is a premier journal dedicated to the dissemination of cutting-edge research and clinical advancements in the field of urology. With an impressive impact factor and a recognized status as Q2 within the urology category, this journal offers a vital platform for researchers, practitioners, and students eager to engage with the latest findings and methodologies. Since its inception in 2009, the journal has embraced an Open Access model, ensuring that critical research is freely available to the global community, thereby fostering collaboration and innovation in urological science. Based in New Zealand, it operates within a robust international framework, allowing for a diverse range of contributions that address pressing issues in urology and enhance professional knowledge. Researchers are encouraged to submit their work and become part of this influential discourse, as the journal continues to navigate the rapidly evolving landscape of urological health from 2012 to 2024 and beyond.

Urology Practice

Transforming urological care through rigorous scholarship.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2352-0779Frequency: 6 issues/year

Urology Practice is a distinguished journal dedicated to advancing knowledge and practice in the field of urology. Published by Lippincott Williams & Wilkins, this journal has been pivotal in providing a platform for the dissemination of innovative research and clinical findings since its inception in 2014. With an ISSN of 2352-0779 and an E-ISSN of 2352-0787, the journal is indexed in Scopus, ranking #73 out of 120 in the Urology category, placing it in the 39th percentile. As part of the Q3 quartile in Urology for 2023, Urology Practice contributes significantly to the evolving landscape of urological medicine, offering vital insights to researchers, healthcare professionals, and students alike. While currently not an open-access journal, its valuable content remains accessible through traditional subscription-based models, catering to a global audience keen on enhancing their expertise in urology. The journal's commitment to excellence and its rigorous peer-review process ensure that published articles uphold the highest standards of scientific integrity, making it an essential resource for those engaged in urological research and clinical practice.

JNCI-Journal of the National Cancer Institute

Elevating the standards of cancer care through scholarly work.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

ONCOLOGIST

Uniting voices in the fight against cancer.
Publisher: OXFORD UNIV PRESSISSN: 1083-7159Frequency: 12 issues/year

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Current Urology

Your Resource for Cutting-Edge Urological Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Journal of Clinical Urology

Advancing Urological Excellence Through Research
Publisher: SAGE PUBLICATIONS LTDISSN: 2051-4158Frequency: 6 issues/year

The Journal of Clinical Urology, published by SAGE Publications Ltd, is a prominent academic platform dedicated to advancing the field of urology and surgical medicine. With an ISSN of 2051-4158 and an E-ISSN of 2051-4166, this journal has been pivotal in disseminating cutting-edge research since its inception in 2008 and is set to continue through 2024. Although categorized in the Q4 quartile for both Surgery and Urology, and positioned in the 24th and 22nd percentiles respectively according to Scopus rankings, the journal remains an essential resource for professionals, researchers, and students who seek to understand clinical developments and innovative practices in urological surgery. While the journal does not operate under an Open Access model, it provides critical insights and valuable findings that significantly impact healthcare practices and patient outcomes in the urology field.

Oncology in Clinical Practice

Empowering Oncology Through Evidence-Based Practice
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Oncology Reviews

Advancing the Frontier of Cancer Research
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Frontiers in Oncology

Connecting researchers to revolutionize oncology.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Prostate International

Leading the charge in prostate health research and innovation.
Publisher: ELSEVIER INCISSN: 2287-8882Frequency: 4 issues/year

Prostate International is a leading open-access journal published by Elsevier Inc, dedicated to advancing research and knowledge in the field of urology, particularly focusing on prostate health and disease. Since its inception in 2013, the journal has preserved its commitment to disseminating high-quality, peer-reviewed articles that contribute significantly to clinical practices and scientific understanding. With an impressive Q1 ranking in urology and a current position as rank #35/120 among urology journals in Scopus, it occupies a prominent place in the academic landscape, ensuring that cutting-edge research reaches a broad audience. The journal's open-access policy enhances visibility and accessibility, fostering collaboration among researchers, healthcare professionals, and students. With the range of topics covered, from innovative treatments to diagnostic advancements, Prostate International serves as a vital resource for those committed to improving patient outcomes and driving the future of urological health.